ELIQUIS® (apixaban) in DVT & PE treatment

HOME / VTE-DVT / PE / OVERVIEW

Choose ELIQUIS^® to help your patients with DVT / PE

ELIQUIS (apixaban) – an oral, direct factor Xa inhibitor - is indicated for:

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.¹

Prevention of Venous Thromboembolic Event (VTE) in adult patients who have undergone elective hip or knee replacement surgery.¹

Robust clinical evidence for ELIQUIS in patients with DVT / PE

AMPLIFY Clinical Trial

ELIQUIS demonstrated comparable efficacy with a significant reduction in the risk of major bleeding vs. enoxaparin / warfarin in the treatment of DVT / PE²

AMPLIFY-EXT Clinical Trial

ELIQUIS significantly reduced the risk of recurrent VTE or all-cause death with no significant difference in the rates of major and major / CRNM bleeding vs. placebo for the prevention of recurrent DVT / PE³

Real-World Data

In AMPLIFY, ELIQUIS demonstrated comparable efficacy, with a superior major bleeding profile vs. Enoxaparin / warfarin; this is now complemented by RWD^2,4

ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.¹

Footnotes:

CRNM = Clinically Relevant Non-Major DVT = Deep Vein Thrombosis PE = Pulmonary Embolism

References:

ELIQUIS^® (apixaban) Summary of Product Characteristics.
Agnelli G et al. N Engl J Med 2013; 369: 799–808.
Agnelli G et al. N Engl J Med 2013; 368: 699–708.
Weycker D et al. Thromb Haemost 2018; 118: 1951–1961.